Hylomorph Overview

  • Founded
  • 2015
Founded
  • Status
  • Private
  • Employees
  • 10
Employees
  • Latest Deal Type
  • Series B
  • Latest Deal Amount
  • $6.61M
Latest Deal Amount
  • Investors
  • 11

Hylomorph General Information

Description

Provider of healthcare biomaterials intended to optimize the interface between implantable medical devices and biological tissues. The company's bio-engineered implants prevent postoperative complications in implantable medical devices such as fibrosis, infection, migration, deploys advanced methods combining biotech and surface micro-engineering to promote optimal interaction between human tissues and foreign implants and first indication for use in cardiac pacemakers and defibrillators, and neurostimulators, enabling users to improve the quality of life of patients and the quality of care by healthcare professionals.

Contact Information

Website
www.hylomorph-medical.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Devices and Supplies
Primary Office
  • Technoparkstrasse 1
  • 8005 Zurich
  • Switzerland

Hylomorph Timeline

2019202020212022
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Hylomorph Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC (Series B) 06-Dec-2021 $6.61M 000.00 000.00 Completed Clinical Trials - General
7. Accelerator/Incubator 31-Jan-2020 00.000 Completed Clinical Trials - General
6. Secondary Transaction - Private 00.000 Completed Clinical Trials - General
5. Early Stage VC (Series A) 14-Sep-2018 00.000 00.000 000.00 Completed Clinical Trials - General
4. Accelerator/Incubator 00.000 00000 Completed Startup
3. Accelerator/Incubator 000.00 00000 Completed Startup
2. Early Stage VC 22-Aug-2016 $114K $114K 00.000 Completed Startup
1. Accelerator/Incubator Completed Startup
To view Hylomorph’s complete valuation and funding history, request access »

Hylomorph Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B 000,000 00.000000 00.00 00.00 00 00.00 00.000
Series A 000,000 00.000000 00.00 00.00 00 00.00 00.000
Ordinary 111,111 $0.108338 $1.08 $1.08 1x $1.08 4.81%
To view Hylomorph’s complete cap table history, request access »

Hylomorph Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Provider of healthcare biomaterials intended to optimize the interface between implantable medical devices and biologica
Other Devices and Supplies
Zurich, Switzerland
10 As of 2021
000.00
00.00 0000-00-00
00000000000 000.00

00000

dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui
00000000 0000000
Columbia, MD
000 As of 0000
000.00
0000 0000-00-00
000000&0 000.00

00000 00

e eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui offici
0000000000000
Silver Spring, MD
000 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Hylomorph Competitors (2)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
ACell Formerly VC-backed Columbia, MD 000 000.00 000000&0 000.00
00000 000000000 Formerly PE-Backed Silver Spring, MD 000 00000 000000000 00000
You’re viewing 2 of 2 competitors. Get the full list »

Hylomorph Executive Team (6)

Name Title Board Seat Contact Info
Simone Bottan Ph.D Co-Founder, Chief Executive Officer & Board Member
Francesco Robotti Chief Operating Officer
Aldo Ferrari Chief Scientific Officer & Board Member
Sonia Schmocker Chief Regulatory and Quality Officer
Gian-Luigi Berini Chairman
You’re viewing 5 of 6 executive team members. Get the full list »

Hylomorph Board Members (4)

Name Representing Role Since
Aldo Ferrari Hylomorph Chief Scientific Officer & Board Member 000 0000
Gian-Luigi Berini Hylomorph Chairman 000 0000
Peter Gabriel Self Board Member 000 0000
Simone Bottan Ph.D Hylomorph Co-Founder, Chief Executive Officer & Board Member 000 0000
To view Hylomorph’s complete board members history, request access »

Hylomorph Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Hylomorph Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Geneva Funds Mutual Fund Minority 000 0000 000000 0
Geneva Smart Invest Venture Capital Minority 000 0000 000000 0
Startup Angel Network Angel Group Minority 000 0000 000000 0
European Commission Government 000 0000 000000 0
StartAngels Network Angel Group Minority 000 0000 000000 0
You’re viewing 5 of 11 investors. Get the full list »

Ready to get started?

Request a free trial